Astellas Pharma (OTCMKTS:ALPMY) Reaches New 12-Month High – Still a Buy?

Astellas Pharma Inc. (OTCMKTS:ALPMY)’s stock price hit a new 52-week high during trading on Thursday . The company traded as high as $15.40 and last traded at $15.37, with a volume of 147490 shares changing hands. The stock had previously closed at $14.11.

Wall Street Analyst Weigh In

ALPMY has been the topic of a number of research reports. Citigroup downgraded Astellas Pharma from a “strong-buy” rating to a “hold” rating in a report on Monday, January 19th. Zacks Research downgraded shares of Astellas Pharma from a “strong-buy” rating to a “hold” rating in a report on Wednesday, October 22nd. Three analysts have rated the stock with a Hold rating, According to data from MarketBeat.com, the company presently has a consensus rating of “Hold”.

Astellas Pharma Price Performance

The company has a quick ratio of 0.80, a current ratio of 1.03 and a debt-to-equity ratio of 0.20. The company has a market capitalization of $27.81 billion, a price-to-earnings ratio of 32.70 and a beta of 0.18. The stock’s 50-day moving average price is $13.62 and its 200-day moving average price is $11.98.

Astellas Pharma Company Profile

Astellas Pharma Inc is a Tokyo-based, global pharmaceutical company traded in the United States as an American Depositary Receipt on the OTC Markets under the symbol ALPMY. The company focuses on discovering, developing and marketing prescription medicines in key therapeutic areas, including oncology, urology, immunology, neuroscience and cardiovascular/metabolic diseases. Astellas seeks to bring innovative treatments to market by combining internal research capabilities with external partnerships and collaborative agreements around the world.

Core products in Astellas’ portfolio include the immunosuppressant Prograf (tacrolimus), the overactive bladder treatments Vesicare (solifenacin) and Myrbetriq (mirabegron), and the prostate cancer therapy Xtandi (enzalutamide).